Artelo Biosciences reports positive preclinical data for ART26.12 in spinal cord injury neuropathic pain model

Artelo Biosciences Inc

Artelo Biosciences Inc

ARTL

0.00
  • Artelo reported positive preclinical data for ART26.12 in a mouse model of spinal cord injury-related neuropathic pain.
  • Study showed reduced mechanical hypersensitivity, lower spontaneous pain behaviors, suppressed nociceptor hyperexcitability, improved outcomes with oral dosing.
  • Company positioned ART26.12, a selective FABP5 inhibitor, as a potential first-in-class non-opioid chronic pain therapy; program remains in Phase 1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010842PRIMZONEFULLFEED9755539) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.